AM-087, a member of the AM cannabinoid series, is an analgesic medication functioning as a cannabinoid agonist. Derived from Δ8-THC, it features a substitution on the 3-position side chain. AM-087 stands out as a potent CB1 agonist, boasting a Ki value of 0.43 nM, rendering it approximately 100 times more potent than THC. This enhanced potency is attributed to the substantial bromine substituent on the side chain.

IUPAC name
CAS Number152674-96-9 
PubChem CID10717065
Chemical and physical data
Molar mass421.419 g·mol−1


1. What is AM-087?

AM 087 is a synthetic compound and part of the AM cannabinoid series. It is used as an analgesic drug and functions as a cannabinoid agonist.

2. How is AM-087 different from THC?

AM-087 is derived from Δ8-THC, a close relative of the more well-known Δ9-THC found in cannabis. AM-087 modifies the 3-position side chain, making it substantially more potent than Δ9-THC.

3. What are the analgesic properties of AM-087?

AM-087 is used for its analgesic or pain-relieving properties. It acts as a cannabinoid agonist, interacting with the endocannabinoid system to potentially provide relief from pain.

4. How does AM-087 compare to THC in terms of potency?

AM-087 is approximately 100 times more potent than Δ9-THC, the psychoactive compound found in cannabis. This increased potency is primarily attributed to a bulky bromine substituent on the side chain.

5. What conditions or ailments is AM-087 used to treat?

AM-087 is primarily used for research purposes, and its therapeutic potential is still being explored. It may have applications in pain management, but further research is needed to understand its full range of potential medical uses.

6. Is AM-087 legal for recreational or medical use?

AM-087 is typically not intended for recreational or medical use. It is primarily used in research settings to understand its pharmacological properties better. Its legality and intended use may vary by jurisdiction, so it is crucial to adhere to local laws and regulations.

7. Are there potential risks or side effects associated with AM-087 use?

As with any synthetic compound, there may be potential risks or side effects associated with using AM-087. Researchers and individuals should exercise caution and adhere to ethical and legal guidelines when working with this substance.

8. Is AM-087 regulated under international drug control conventions?

Information regarding AM-087’s status in international drug control conventions is not provided in the original text. Still, it’s important to know any international regulations governing its use and distribution.

9. Can AM-087 be legally obtained for research purposes?

The legal availability of AM-087 for research purposes can vary by jurisdiction. Researchers should familiarize themselves with local regulations, seek necessary approvals, and obtain the appropriate licenses for its acquisition and use in scientific studies.

10. What are the potential future applications of AM-087 in medicine or research?

AM-087’s future applications may include further exploration of its pain-relieving properties and potential therapeutic uses. Continued research may uncover its utility in specific medical conditions or as a reference compound in cannabinoid research.


  1. In October 1993, a study by Martin BR and his team evaluated the pharmacology of iodo and nitro analogs of Δ8-THC and Δ9-THC. Their research, featured in “Pharmacology, Biochemistry, and Behavior,” provided valuable insights into the properties of these analogs. [DOI: 10.1016/0091-3057(93)90356-X] [PMID: 8265683] [S2CID: 140209578]
  2. In November 1991, Charalambous A, Lin S, and their colleagues conducted a pharmacological evaluation of halogenated delta 8-THC analogs. This research, also published in “Pharmacology, Biochemistry, and Behavior,” explored the effects of halogen substitutions on delta 8-THC analogs. [DOI: 10.1016/0091-3057(91)90355-6] [PMID: 1666915] [S2CID: 140209927]

Leave a Comment

Your email address will not be published. Required fields are marked *